Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348330 | 0.80 | DDB1 (0.56) | DDB1CRBN | |
| SCHEMBL31068105 | 0.80 | DDB1 (0.56) | DDB1CRBN | |
| SCHEMBL30937053 | 0.78 | DDB1 (0.38) | DDB1CRBN | |
| SCHEMBL30937133 | 0.77 | CRBN (0.51) | DDB1CRBNPOLB | |
| SCHEMBL29348374 | 0.73 | DDB1 (0.46) | DDB1CRBN | |
| SCHEMBL31637586 | 0.71 | CRBN (0.46) | DDB1CRBNPOLB | |
| SCHEMBL26049118 | 0.71 | DDB1 (0.73) | DDB1CRBNPOLB | |
| SCHEMBL30349444 | 0.71 | CRBN (0.50) | DDB1CRBN | |
| SCHEMBL26438261 | 0.71 | CRBN (0.50) | DDB1CRBN | |
| SCHEMBL30937100 | 0.71 | CRBN (0.52) | DDB1CRBNPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224262-A1 | COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| EP-4608816-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Monte Rosa Therapeutics AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024092039-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |